{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:05:28Z","timestamp":1778814328769,"version":"3.51.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Mol Allergy"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Omalizumab, a humanized monoclonal anti-IgE antibody has the potential to alter allergen processing. Recently, it has been postulated the assessment of PHA-stimulated adenosine triphosphate (ATP) activity as maker of CD4+ T cells activity in peripheral blood cells. We present the case report of a 35-year-old woman with a history of chronic idiopathic urticaria and angioedema of 8 years of development with poor response to treatment. The patient was partially controlled with cyclosporine at doses of 100 mg\/12 h. However, she was still developing hives daily. Finally treatment with omalizumab was started at dose of 300 mg every 2 weeks. The patient experienced a decrease in urticarial lesions 2 days after starting therapy. We also evaluated the effects of omalizumab therapy on the activity of peripheral blood CD4+ T cells from the patient, in order to determine the potential modification of anti-IgE therapy on the process of antigen presentation-recognition. Activity of CD4+ cells by ATP release was clearly increased demonstrating an enlarged CD4 activity. Omalizumab may be useful in the treatment of severe chronic urticaria. ATP activity of peripheral blood CD4+ T cells might be a non-subjective method to assess Omalizumab activity.<\/jats:p>","DOI":"10.1186\/1476-7961-9-11","type":"journal-article","created":{"date-parts":[[2011,7,26]],"date-time":"2011-07-26T18:22:30Z","timestamp":1311704550000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["T cell activity in successful treatment of chronic urticaria with omalizumab"],"prefix":"10.1186","volume":"9","author":[{"given":"Inmaculada","family":"S\u00e1nchez-Mach\u00edn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Iglesias-Souto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvelise","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruperto","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Matheu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,7,26]]},"reference":[{"issue":"1","key":"96_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1476-7961-9-2","volume":"9","author":"MC Saavedra","year":"2011","unstructured":"Saavedra MC, Sur S: Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumab. Clin Mol Allergy. 2011, 9 (1): 2. 10.1186\/1476-7961-9-2","journal-title":"Clin Mol Allergy"},{"issue":"2","key":"96_CR2","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S1081-1206(10)60644-8","volume":"99","author":"SL Spector","year":"2007","unstructured":"Spector SL, Tan RA: Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol. 2007, 99 (2): 190-193. 10.1016\/S1081-1206(10)60644-8","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"96_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1398-9995.2007.01591.x","volume":"63","author":"M Metz","year":"2008","unstructured":"Metz M, Bergmann P, Zuberbier T, Maurer M: Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy. 2008, 63 (2): 247-249. 10.1111\/j.1398-9995.2007.01591.x","journal-title":"Allergy"},{"issue":"6","key":"96_CR4","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.jaci.2007.07.037","volume":"120","author":"V Matheu","year":"2007","unstructured":"Matheu V, Franco A, Perez E, Hernandez M, Barrios Y: Omalizumab for drug allergy. J Allergy Clin Immunol. 2007, 120 (6): 1471-1472. author reply 1472-1473.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"96_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jaci.2010.05.047","volume":"126","author":"M Magerl","year":"2010","unstructured":"Magerl M, Staubach P, Altrichter S, Ardelean E, Krause K, Metz M, Weller K, Maurer M: Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. J Allergy Clin Immunol. 2010, 126 (3): 665-666. 10.1016\/j.jaci.2010.05.047","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"96_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2340\/00015555-0884","volume":"90","author":"C Vestergaard","year":"2010","unstructured":"Vestergaard C, Deleuran M: Two cases of severe refractory chronic idiopathic urticaria treated with omalizumab. Acta Derm Venereol. 2010, 90 (4): 443-444. 10.2340\/00015555-0884","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"96_CR7","first-page":"252","volume":"20","author":"E Iemoli","year":"2010","unstructured":"Iemoli E, Piconi S, Fusi A, Borgonovo L, Borelli M, Trabattoni D: Immunological effects of omalizumab in chronic urticaria: a case report. J Investig Allergol Clin Immunol. 2010, 20 (3): 252-254.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"6","key":"96_CR8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.jaci.2003.10.003","volume":"112","author":"C Prussin","year":"2003","unstructured":"Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB: Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol. 2003, 112 (6): 1147-1154. 10.1016\/j.jaci.2003.10.003","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"96_CR9","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.jaci.2008.07.006","volume":"122","author":"AP Kaplan","year":"2008","unstructured":"Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK: Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol. 2008, 122 (3): 569-573. 10.1016\/j.jaci.2008.07.006","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"96_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000112504","volume":"146","author":"O Noga","year":"2008","unstructured":"Noga O, Hanf G, Kunkel G, Kleine-Tebbe J: Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. Int Arch Allergy Immunol. 2008, 146 (1): 66-70. 10.1159\/000112504","journal-title":"Int Arch Allergy Immunol"},{"issue":"7","key":"96_CR11","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.humimm.2010.03.011","volume":"71","author":"K Manga","year":"2010","unstructured":"Manga K, Serban G, Schwartz J, Slotky R, Patel N, Fan J, Bai X, Chari A, Savage D, Suciu-Foca N: Increased adenosine triphosphate production by peripheral blood CD4+ cells in patients with hematologic malignancies treated with stem cell mobilization agents. Hum Immunol. 2010, 71 (7): 652-658. 10.1016\/j.humimm.2010.03.011","journal-title":"Hum Immunol"},{"issue":"2, pt1","key":"96_CR12","doi-asserted-by":"publisher","first-page":"s38","DOI":"10.1016\/j.jaci.2007.12.157","volume":"121","author":"V Matheu","year":"2008","unstructured":"Matheu V, Perez E, Gonzalez R, Franco A, Garc\u00eda-Robaina J, Barrios Y: T cell activation after Omalizumab for insulin allergy. J Allergy Clin Immunol. 2008, 121 (2, pt1): s38.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Clinical and Molecular Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1476-7961-9-11.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T15:34:30Z","timestamp":1630510470000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalmolecularallergy.biomedcentral.com\/articles\/10.1186\/1476-7961-9-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,26]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["96"],"URL":"https:\/\/doi.org\/10.1186\/1476-7961-9-11","relation":{},"ISSN":["1476-7961"],"issn-type":[{"value":"1476-7961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,26]]},"assertion":[{"value":"1 April 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"11"}}